We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-12.69%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$289M
AUM Growth
-$11.6M
Cap. Flow
+$6.66M
Cap. Flow %
2.3%
Top 10 Hldgs %
62.75%
Holding
82
New
19
Increased
–
Reduced
–
Closed
22

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$17M
2
CYTK icon
Cytokinetics
CYTK
+$16.9M
3
FOLD
Amicus Therapeutics
FOLD
+$16.6M
4
SAGE
Sage Therapeutics
SAGE
+$15.9M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$15.5M

Top Sells

Rank Stock Value
1
REVH
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
+$21.2M
2
HAAC
Health Assurance Acquisition Corp. Class A Common Stock
HAAC
+$18.1M
3
CCV
Churchill Capital Corp V
CCV
+$17.8M
4
CCVI
Churchill Capital Corp VI
CCVI
+$16.8M
5
CPAR
Catalyst Partners Acquisition Corp. Class A Ordinary Share
CPAR
+$16.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.56%
2 Materials 11.54%
3 Energy 0%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASTL icon
1
Algoma Steel
ASTL
$404M
$33.4M 11.54%
3,716,732
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$21.6M 7.47%
+2,010,900
New +$16.6M
ARGX icon
3
argenx
ARGX
$53.8B
$20M 6.92%
+52,800
New +$17M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$16.5M 5.7%
+419,433
New +$16.9M
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.82B
$15.8M 5.47%
+211,000
New +$15.5M
SAGE
6
DELISTED
Sage Therapeutics
SAGE
$15.4M 5.31%
+475,600
New +$15.9M
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
$15.1M 5.24%
+474,000
New +$13.9M
ASND icon
8
Ascendis Pharma A/S
ASND
$17.1B
$14.8M 5.13%
+159,500
New +$15M
LKFT
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$14.5M 5.01%
+259,400
New +$15.4M
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
$14.4M 4.98%
+318,400
New +$14.5M
TVTX icon
11
Travere Therapeutics
TVTX
$5.27B
$14.2M 4.9%
+584,300
New +$14.7M
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$14.1M 4.88%
+210,200
New +$13.4M
RCUS icon
13
Arcus Biosciences
RCUS
$3.44B
$13.6M 4.69%
+535,000
New +$13.1M
PRTA icon
14
Prothena Corp
PRTA
$453M
$12.4M 4.29%
+457,500
New +$13.4M
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.88B
$12.1M 4.19%
+203,200
New +$12.5M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.23B
$10.6M 3.67%
+960,200
New +$12.6M
ACAD icon
17
Acadia Pharmaceuticals
ACAD
$4.38B
$9.96M 3.45%
+707,200
New +$13.2M
ISEE
18
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.5M 3.29%
+987,600
New +$12.4M
PTGX icon
19
Protagonist Therapeutics
PTGX
$9.06B
$5.82M 2.01%
+735,126
New +$8.89M
GBTG.WS
20
DELISTED
Global Business Travel Group, Inc. Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
GBTG.WS
$959K 0.33%
+913,000
New +$1.06M
CRHC.WS
21
DELISTED
Cohn Robbins Holdings Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
CRHC.WS
$389K 0.13%
904,000
– –
IPOF.WS
22
DELISTED
Social Capital Hedosophia Holdings Corp. VI Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
IPOF.WS
$322K 0.11%
671,000
– –
STRY.WS
23
DELISTED
Starry Group Holdings, Inc. Warrants, each whole warrant exercisable to purchase 1.2415 shares of Class A common stock at an exercise price of $11.50 per 1.2415 shares of Class A common stock
STRY.WS
$276K 0.1%
669,000
– –
KAHC.WS
24
DELISTED
KKR Acquisition Holdings I Corp. Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
KAHC.WS
$212K 0.07%
588,547
– –
BTWNW
25
DELISTED
Bridgetown Holdings Limited Warrants
BTWNW
$206K 0.07%
895,000
– –
1
2 3 4

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Finepoint Capital held 82 positions worth $289M, down 3.9% from $301M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Finepoint Capital's Q2 2022 filing shows 19 new and 22 closed positions. Its largest new stake was argenx: 52,800 shares worth $20M. The largest sale was Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock, an estimated $21.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 0% a quarter earlier, followed by Materials and Energy.

  • Finepoint Capital's largest Q2 2022 buy was argenx: 52,800 shares worth $20M.
  • Finepoint Capital fully exited Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock in Q2 2022, selling an estimated $21.2M.
  • Finepoint Capital's ten largest holdings make up 63% of its $289M portfolio in Q2 2022.
  • Finepoint Capital opened 19 new positions and closed 22 in Q2 2022.
  • Finepoint Capital's portfolio value fell 3.9% quarter-over-quarter to $289M.

Based on Finepoint Capital's 13F filing for Q2 2022, filed 12 Aug 2022.